{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029723","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.171382+00:00","generated_at":"2026-06-11T06:09:31.064105+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Propanc Biopharma enters $55K convertible note and $132K promissory note financings","bullets":["Issued $55,000 convertible promissory note to 1800 Diagonal Lending LLC, convertible at 65% of market price after 180 days, 8% interest, matures Aug 16, 2024.","Issued $132,000 face (10% OID) promissory note for $120,000 proceeds, 10% interest, matures Nov 15, 2023; prepayable at 110%-130% premium.","Proceeds from both notes will be used for general working capital; notes issued under Section 4(a)(2) and Rule 506 private placement exemptions.","Convertible note includes prepayment options with escalating premiums (110% to 129% within 180 days) and default triggers 150% acceleration.","Promissory note default interest increases to 18%; Company must maintain corporate existence and cannot sell substantially all assets without consent."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029723","json":"https://secwatch.observer/filing/0001493152-23-029723.json","markdown":"https://secwatch.observer/filing/0001493152-23-029723.md","text":"https://secwatch.observer/filing/0001493152-23-029723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:09:31.064105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07990ced4a87c5e605d5e2fbf6ff84d2f1cf202c","claim":"Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $55,000 with August Investor at 8% per annum, which may be increased to 22% in the event of a default maturing August 16, 2024.","evidence_excerpt":"On August 16, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “August Investor”), which closed on August 16, 2023, pursuant to which the August Investor purchased a convertible promissory note (the “August Note”) from the Company in the aggregate principal amount of $55,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"aggregate principal amount of $55,000"},{"label":"Counterparty","value":"August Investor"},{"label":"Rate","value":"8% per annum, which may be increased to 22% in the event of a default"},{"label":"Maturity","value":"August 16, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"81a7639ed8b59952280af70cec2563b3e07135ec","claim":"Propanc Biopharma, Inc. incurred loan of principal face amount of $132,000 with August Lender at 10% per annum, which may be increased to 18% in the event of a default maturing November 15, 2023.","evidence_excerpt":"On August 15, 2023, the Company issued to an institutional investor (the “August Lender”) a 10% original issue discount promissory note (the “Promissory Note”) in consideration for $120,000, which has a principal face amount of $132,000, matures on November 15, 2023 and accrues interest at a rate of 10% per annum, which may be increased to 18% in the event of a default.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"principal face amount of $132,000"},{"label":"Counterparty","value":"August Lender"},{"label":"Rate","value":"10% per annum, which may be increased to 18% in the event of a default"},{"label":"Maturity","value":"November 15, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"14bb1ce81448253ee95e5af3c4b9e99f84e89847","claim":"Propanc Biopharma, Inc. entered into Promissory Note with an institutional investor (the “August Lender”) valued at $132,000 (effective 2023-08-15).","evidence_excerpt":"On August 15, 2023, the Company issued to an institutional investor (the “August Lender”) a 10% original issue discount promissory note (the “Promissory Note”) in consideration for $120,000, which has a principal face amount of $132,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"an institutional investor (the “August Lender”)"},{"label":"Value","value":"$132,000"},{"label":"Effective","value":"2023-08-15"}],"fact_type":"material_agreement"},{"claim_id":"a69465b8b3668906c91d57ef3754dd8fa7b76b28","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “August Investor”) valued at $55,000 (effective 2023-08-16).","evidence_excerpt":"On August 16, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “August Investor”), which closed on August 16, 2023, pursuant to which the August Investor purchased a convertible promissory note (the “August Note”) from the Company in the aggregate principal amount of $55,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an investor (the “August Investor”)"},{"label":"Value","value":"$55,000"},{"label":"Effective","value":"2023-08-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}